Celldex Therapeutics Stock
Price
Target price
€18.90
€18.90
-7.350%
-1.5
-7.350%
€38.34
06.02.26 / Frankfurt
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
Heavy losses for Celldex Therapeutics today as the stock fell by -€1.500 (-7.350%).
Currently there is a rather positive sentiment for Celldex Therapeutics with 8 Buy predictions and 3 Sell predictions.
Based on the current price of 18.9 € the target price of 38 € shows a potential of 101.06% for Celldex Therapeutics which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | -7.350% | -7.353% | -13.303% | -17.826% | -14.091% | -55.043% | -5.025% |
| Larimar Therapeutics Inc. | -1.550% | -13.605% | -11.806% | -26.163% | -23.494% | -47.737% | -83.067% |
| aTyr Pharma Inc | -10.690% | 0.000% | 9.346% | -84.441% | -2.500% | -71.996% | -85.662% |
| Inotiv Inc. | 5.670% | -17.222% | -40.400% | -92.587% | -30.374% | -95.973% | -97.050% |
Comments
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics SVPs Engage In Heavy Transactions
On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.
